Cardiovascular Systems, Inc., announces the first patient enrollment in its prospective, randomized CALCIUM 360° clinical trial, part of the company’s 360° Clinical Series. The CALCIUM 360° study will evaluate the treatment of peripheral arterial disease (PAD) behind and below the knee using CSI’s Diamondback 360® PAD System, a minimally invasive catheter for treating PAD anywhere in the leg. [More]

A new analysis published by THE SAGE GROUP concludes that atherosclerotic peripheral arterial disease (PAD) afflicts over 20 million in India. Both PAD and CLI represent major and significantly underestimated problems for the Indian economy and healthcare system. [More]

The Society of Interventional Radiology offers numerous resources-including publications and the first-ever Catheter Lysis of Thromboembolic Stroke (CLOTS) course-for interventional radiologists, neuroradiologists, neurointerventionists, body interventionalists, and IR and INR fellows to aid in the understanding of stroke and carotid artery disease. [More]

Catheter-directed therapy or catheter-directed thrombolysis-an interventional radiology treatment that uses targeted image-guided drug delivery with specially designed catheters to dissolve dangerous blood clots in the lungs-saves lives and should be considered a first-line treatment option for massive pulmonary embolism, note researchers in the November Journal of Vascular and Interventional Radiology. [More]

Registration is now open for the Society of Interventional Radiology's "Image-guided Interventional Oncology (IO) Therapies" Webinar, which will provide the latest updates on percutaneous and transcatheter treatment of liver tumors, kidney tumor ablation and lung tumor ablation. [More]

Declining kidney function is linked to a higher risk of heart failure, heart attack, peripheral arterial disease, and early death in individuals with or without kidney disease, according to a pair of studies appearing in an upcoming issue of the Journal of the American Society Nephrology (JASN). [More]

Vascular surgeons have the highest market share and the lowest overall mortality and morbidity rates for peripheral arterial interventions (PAI), when compared to interventional cardiologists and interventional radiologists who also perform this procedure. [More]

Boehringer Ingelheim announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Evaluation Agency (EMEA) has issued a positive opinion for the approval of MICARDIS® (telmisartan) for the reduction of cardiovascular morbidity. [More]

On Saturday, November 7, 2009 Vasamed Inc., provider of diagnostic technologies that detect peripheral arterial disease in patients with diabetes, will partner with the Black Barbershop Health Outreach Program (BBHOP) in its mission to help African Americans identify the connection between peripheral arterial disease (PAD), diabetes, obesity and hypertension through early detection and referral to appropriate medical resources. [More]

Modifying the risk of peripheral arterial disease (or PAD)-with healthy lifestyle changes-remains vital to one's health, note researchers in a recent issue of the Journal of Vascular and Interventional Radiology. And while PAD can progress and worsen over time, there is not enough evidence yet to advocate minimally invasive treatment in patients who have had a narrowing or blockage of a leg artery but showing no signs or symptoms of the disease, say Irish researchers in a retrospective study of more than 900 individuals. [More]

Research and Markets (http://www.researchandmarkets.com/research/44f560/stateoftheart_i) has announced the addition of the "State-of-the-Art Imaging and Interventional Radiology" training to their offering. [More]

Boehringer Ingelheim Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application (sNDA) for its angiotensin II receptor blocker (ARB) Micardis® (telmisartan) Tablets 80 mg for reduction of the risk of myocardial infarction, stroke, or death from cardiovascular causes in patients 55 years of age or older at high risk of developing major cardiovascular events who are unable to take angiotensin-converting enzyme (ACE) inhibitors.(1) MICARDIS is the most studied ARB in this high-risk patient population and has been commercially available to treat hypertension (high blood pressure) since its approval in 1998. [More]

Cardiovascular Systems, Inc. (CSI), a medical device company developing and commercializing innovative interventional treatment systems for vascular disease, has signed a 10-year lease agreement for a new 46,000-square-foot manufacturing facility in Pearland, Texas. [More]

The Society of Interventional Radiology presents Catheter Lysis of Thromboembolic Stroke (CLOTS)-an intensive five-day course featuring top interventional radiologists, neurointerventionists, neurologists and neuroradiologists offering doctors the opportunity to gain and/or upgrade skills to incorporate acute ischemic stroke care into their practice. [More]

The Society of Interventional Radiology Foundation recently received a $1 million planned-gift donation to create a future scholarship fund for interventional radiology fellows to pursue this medical profession. SIR Foundation is dedicated to advancing the clinical needs of interventional radiology by specializing in developing investigators trained in conducting pivotal basic and clinical trials research. [More]